Literature DB >> 11208637

Low-flow oxygen and bilevel ventilatory support: effects on ventilation during sleep in cystic fibrosis.

M A Milross1, A J Piper, M Norman, H F Becker, G N Willson, R R Grunstein, C E Sullivan, P T Bye.   

Abstract

We measured ventilation in all sleep stages in patients with cystic fibrosis (CF) and moderate to severe lung disease, and compared the effects of low-flow oxygen (LFO2) and bilevel ventilatory support (BVS) on ventilation and gas exchange during sleep. Thirteen subjects, age 26 +/- 5.9 yr (mean +/- 1 SD), body mass index (BMI) 20 +/- 3 kg/m2, FEV1 32 +/- 11% predicted, underwent three sleep studies breathing, in random order, room air (RA), LFO2, and BVS +/- O2 with recording of oxyhemoglobin saturation (SpO2) (%) and transcutaneous carbon dioxide (TcCO2) (mm Hg). During RA and LFO2 studies, patients wore a nasal mask with a baseline continuous positive airway pressure (CPAP) of 4 to 5 cm H2O. Minute ventilation (V I) was measured using a pneumotachograph in the circuit and was not different between wake and non-rapid eye movement (NREM) sleep on any night. However, V I was reduced on the RA and LFO2 nights from awake to rapid eye movement (REM) (p < 0.01) and from NREM to REM (p < 0.01). On the BVS night there was no significant difference in V I between NREM and REM sleep. Both BVS and LFO2 improved nocturnal SpO2, especially during REM sleep (p < 0.05). The rise in TcCO2 seen with REM sleep with both RA and LFO2 was attenuated with BVS (p < 0.05). We conclude that BVS leads to improvements in alveolar ventilation during sleep in this patient group.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11208637     DOI: 10.1164/ajrccm.163.1.2005130

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  15 in total

Review 1.  The heart in cystic fibrosis.

Authors:  Rowland J Bright-Thomas; A Kevin Webb
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

2.  Randomised controlled trial of non-invasive ventilation (NIV) for nocturnal hypoventilation in neuromuscular and chest wall disease patients with daytime normocapnia.

Authors:  S Ward; M Chatwin; S Heather; A K Simonds
Journal:  Thorax       Date:  2005-12       Impact factor: 9.139

Review 3.  Sleep disturbances and their impact in pediatric cystic fibrosis.

Authors:  Aarti Shakkottai; Louise M O'Brien; Samya Z Nasr; Ronald D Chervin
Journal:  Sleep Med Rev       Date:  2018-07-06       Impact factor: 11.609

4.  Sleep findings and predictors of sleep desaturation in adult cystic fibrosis patients.

Authors:  Christiano Perin; Simone C Fagondes; Fernanda C Casarotto; Antônio F F Pinotti; Sérgio S Menna Barreto; Paulo de Tarso R Dalcin
Journal:  Sleep Breath       Date:  2011-09-25       Impact factor: 2.816

Review 5.  Non-invasive ventilation for cystic fibrosis.

Authors:  Fidelma Moran; Judy M Bradley; Amanda J Piper
Journal:  Cochrane Database Syst Rev       Date:  2017-02-20

Review 6.  Oxygen therapy for cystic fibrosis.

Authors:  Heather E Elphick; George Mallory
Journal:  Cochrane Database Syst Rev       Date:  2013-07-25

7.  [Relevance of sleep for patients with lung diseases].

Authors:  H F Becker
Journal:  Internist (Berl)       Date:  2004-09       Impact factor: 0.743

8.  Sleep and non-invasive ventilation in patients with chronic respiratory insufficiency.

Authors:  Cristina Ambrogio; Xazmin Lowman; Ming Kuo; Joshua Malo; Anil R Prasad; Sairam Parthasarathy
Journal:  Intensive Care Med       Date:  2008-09-16       Impact factor: 17.440

Review 9.  Sleep disorders in cystic fibrosis: A systematic review and meta-analysis.

Authors:  Joel Reiter; Alex Gileles-Hillel; Malena Cohen-Cymberknoh; Dennis Rosen; Eitan Kerem; David Gozal; Erick Forno
Journal:  Sleep Med Rev       Date:  2020-02-19       Impact factor: 11.609

10.  Sleep-disordered breathing in cystic fibrosis.

Authors:  Aarti Shakkottai; Samya Z Nasr; Fauziya Hassan; Sanaya Irani; Louise M O'Brien; Ronald D Chervin
Journal:  Sleep Med       Date:  2020-06-05       Impact factor: 3.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.